The FDA panel vote is a significant event for Medtronic as it could potentially lead to the approval or disapproval of its Symplicity Spyral Renal Denervation System. This could have a direct impact on the company's revenues and, consequently, its stock price. However, without specific details on the vote outcome, it's difficult to predict the direction of the impact.